Survival Of Human Cancer Patients Research Articles

Multiomics analysis of altered NRF3 expression reveals poor prognosis in cancer

The alliance of NRF3 expression with human cancer patient survival and the underlying function of this gene in liaison to various cancers progression has not been comprehensively studied. In addition, the molecular mechanism of the NRF3 gene and its relationship to cancer patient survival and prognosis are still poorly understood. To elucidate the carcinogenic activity of NRF3, we systematically analyzed the NRF3 expression and its prognostic relevance in diverse cancer patients to decipher the oncogenic function of NRF3. Therefore, we systematically investigated the expression level of NRF3 and its relationship with patient survival as well as the affected pathways in breast, colorectal adenocarcinoma, renal cancer, pancreatic cancer, and thymoma cancer. Relative expression levels of NRF3 were analyzed using the Oncomine, GEPIA2, GENT, UALCAN, cBioPortal, UCSC Xena and The Cancer Genome Atlas (TCGA) databases. Gene copy number of NRF3 was analyzed using cBioPortal, and the subsequent patient prognosis and risk factors were analyzed by obtaining the data from GEPIA2, GENT, and PrognoScan databases. Besides, gene ontology and pathway analysis of co-expressed genes, and transcriptome data analysis were performed using the Enrichr, which revealed NRF3-related pathways in diverse malignancies. Overall, this open database analysis shows a link between NRF3 expression and cancer patient survival and identifies potential NRF3-mediated pathways that could lead to NRF3 being used as a therapeutic target for a variety of human cancers.

Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: A systemic review and meta-analysis

BackgroundVasculogenic mimicry (VM) has been reported in various malignant tumours and is known to play an important role in cancer progression and metastasis. However, the impact of VM on the overall survival of human cancer patients remains controversial. The goal of this study was to evaluate whether VM is associated with 5-year survival of human cancer patients. MethodsTwenty-two eligible clinical studies with data on both tumour cell-dominant VM and the 5-year survival of 3062 patients involved in 15 types of cancers were pooled in the meta-analysis. ResultsThe 5-year overall survival of VM-positive and -negative cancer patients was 31% and 56%, respectively. The relative risk (RR) of the 5-year survival of VM-positive patients was significantly higher than that of VM-negative cases (RR=1.531; 95% confidence interval (CI): 1.357–1.726; P<0.001). Notably, metastatic melanoma patients demonstrated a higher VM rate (45.3%) than patients with primary melanoma (23.1%) and showed worse 5-year survival, suggesting that VM contributes to tumour metastasis and poor prognosis in cancer patients. Subgroup analysis indicated that a poor 5-year survival was significantly associated with eight types of VM-positive malignant tumours, such as lung, colon, liver cancers, sarcomas and melanoma; but was not associated with the seven other types of cancers, such as prostate cancer. Heterogeneity and publication biases were found among the 22 studies, mainly due to the divergent characteristics of cancers and extremely low survival rate in six types of malignant tumours. ConclusionVM-positive cancer patients show a poor 5-year overall survival compared with VM-negative malignant tumour cases, particularly in metastatic cancer.

Effects of short-term dietary restriction on survival of mammary ascites tumor-bearing rats.

We studied the effects of short-term dietary restriction on the survival of 3-4-month-old tumor-free and tumor-bearing Fisher rats. The diet-restricted food regimen consisted of alternate day ad libitum feeding followed by alternate day fasting. Diet-unrestricted control rats were fed ad libitum daily. Six tumor-free rats on the diet-restricted regimen compensated for the dietary restriction by an increase in food consumption during the alternate feeding days, and lost an average of only 2-3% of their weight in 13 days. Six tumor-free rats on a daily ad libitum feeding regimen gained an average of 6.8% in 15 days. The above dietary-restricted regimen was initiated 1 week before 24 rats were inoculated intraperitoneally with 15 million Mat 13762 ascites tumor cells. Sixteen of 24 (66.7%) diet-restricted tumor-bearing hosts and 5/24 (20.8%) diet-unrestricted tumor-bearing hosts survived at 9 days after tumor inoculation (p less than 0.005). Twelve of 24 (50%) diet-restricted tumor-bearing hosts, and 3 of 24 (12.5%) diet-unrestricted tumor-bearing hosts, survived at 10 days after tumor inoculation (p less than 0.025). Thus, the survival of tumor-bearing rats was enhanced by short-term relatively mild dietary restrictions. We suggest that relatively mild dietary restrictions should be included in clinical trials designed to inhibit cancer growth and enhance the survival of human cancer patients.